The Company’s breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.

The Jenex Corporation, the former company name before the name change to Therma Bright Inc., received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). The Jenex Corporation received approval for the above claims from FDA (United States) in 1997. The 510K in the name of The Jenex Corporation is currently not licensed in the US under Therma Bright Inc.  The Company expects to transfer the 510K from The Jenex Corporation to Therma Bright Inc. as it completes R&D and readies its product for commercialization.

Therma Bright Inc. trades on the TSX Venture Exchange (TSXV:THRM). Therma Bright Inc. holds patents pending and the trademarks for Therozap™ and the trademark InterceptCS™ along with with regulatory approvals for its thermal therapy technology.

Copyright Therma Bright Inc. 2018. All Rights Reserved.